ACTRN12605000590662终止3 期
Phase III trial of an immunotherapy for Stage III (AJCC) melanoma based on cultured autologous dendritic cells presenting autologous tumour cell antigens to test the effect on distant disease-free survival at 2 years, time to distant, or untreatable local recurrence and safety.
Queensland Institute of Medical Research (QIMR)0 个研究点目标入组 200 人开始时间: 2005年10月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Histologically confirmed melanoma of Stage III; ECOG status 0; Normal Haematolology; Acceptable Renal and Liver function parameters; Negative serology for HIV, Hep B and C;Informed written consent.
排除标准
- •Autoimmune disease or immunosuppressant use, Prior chemotherapy, immunotherapy, gene therapy, vaccine therapy, cytokine therapy, post-operative complications which would preclude experimental vaccine therapy, Unsuccessful vaccine preparation, Clinically significant active infection, Uncontrolled systemic disease or medical problems, History of other malignancies (except for adequately treated and controlled non-melanomatic skin cancer or in situ cervical cancer), Pregnancy.
研究者
相似试验
招募中
3 期
Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAIRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300
进行中（未招募）
1 期
A trial testing lenalidomide and dexamethasone after standard radiotherapy in patients with solitary bone plasmacytoma who are at a high risk of relapseEUCTR2015-001355-76-GBniversity College London140
进行中（未招募）
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia - CLL10EUCTR2007-007587-21-DKGCLLSG - Dept. of Internal Medicine I, University Hospital Cologne550
进行中（未招募）
1 期
Patients who suffer from chronic lymphocytic leukemia and have not received any chemotherapy so far will be treated with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustine and rituximab (BR)EUCTR2007-007587-21-ATniversity of Cologne, Sponsor-Quality Management550
进行中（未招募）
1 期
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemiaEUCTR2007-007587-21-DEniversity of Cologne550